Advancing a novel product pipeline of neurology therapies
View Product PipelineAbout
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions.
Xenon is advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy.
Read MoreNews
Xenon Announces Appointment of Shelley McCloskey as Senior Vice President, Human Resources
September 17, 2019
Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexion’s Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative Pain
September 9, 2019
Xenon Reports Second Quarter 2019 Financial Results and Provides Corporate Update
August 6, 2019
Xenon to Host Conference Call and Webcast to Discuss Second Quarter 2019 Financial Results and Provide Corporate Update
July 31, 2019
Xenon Presents Corporate Update on Neurology-Focused Pipeline at the Jefferies 2019 Healthcare Conference
June 5, 2019
Product Pipeline
* Xenon has entered into key regulatory and manufacturing agreements related to XEN007; it is anticipated that a Phase 2 clinical trial could be initiated after receiving regulatory feedback.
Investors
Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events
View Investor Area
